Novo Nordisk Smashes Past $500 Billion Value on Wegovy Frenzy
- Danish drugmaker eclipses LVMH amid weight-loss drug fervor
- Operating profit seen rising as much as 29% this year
This article is for subscribers only.
Novo Nordisk A/S became the second-ever European company to pass $500 billion in market value, bolstered by an upbeat outlook for its blockbuster obesity drug.
Novo crossed the milestone on Wednesday, reaching a level only attained by Dior owner LVMH, as its shares extended recent gains.